Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bionomics Ltd (BNOEF)

Bionomics Ltd (BNOEF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 57,672
  • Shares Outstanding, K 544,590
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta 2.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BNOEF with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0920 +14.02%
on 07/29/21
0.1560 -32.76%
on 07/13/21
-0.0366 (-25.87%)
since 06/29/21
3-Month
0.0920 +14.02%
on 07/29/21
0.1953 -46.29%
on 05/03/21
-0.0839 (-44.44%)
since 04/29/21
52-Week
0.0480 +118.54%
on 08/07/20
0.3500 -70.03%
on 02/26/21
+0.0599 (+133.11%)
since 07/27/20

Most Recent Stories

More News
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD

/PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) ( or ), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase trial (the ATTUNE Study) to evaluate...

BNOEF : 0.1049 (-0.94%)
Bionomics BNC210 Expansion into Social Anxiety Disorder

BNC210 is a novel, first-in-class, negative allosteric modulator of the a7 nicotinic acetylcholine receptor in development for the treatment of anxiety and stressor-related disorders, and in was granted...

BNOEF : 0.1049 (-0.94%)
Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results

Agilex Biolabs, Australia's largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today congratulated client Bionomics Limited (Bionomics) on its positive pharmacokinetic...

BNOEF : 0.1049 (-0.94%)
ADCC : 0.0230 (-82.31%)
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced today the appointment of Errol De Souza,...

ARCH : 69.05 (+7.96%)
BIOD : 0.65 (+6.56%)
BNOEF : 0.1049 (-0.94%)
NBIX : 94.20 (+0.30%)
CYCN : 3.08 (-8.06%)
Novamind Increases Strategic Investment in Bionomics

Investment supports phase IIb clinical trial examining novel PTSD treatment

BNOEF : 0.1049 (-0.94%)
NM.CN : 1.010 (+1.00%)
NVMDF : 0.8343 (+0.97%)
Bionomics Successfully Completes A$22.9 million Equity Raise

, /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) () has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on () and concurrent placement that was announced...

BNOEF : 0.1049 (-0.94%)
Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial

The 7-day dosing PK study in ten healthy volunteers (females and males) demonstrated that at a dose of 900 mg given twice daily, the tablet formulation of BNC210 had steady-state 12-hourly exposure levels...

BNOEF : 0.1049 (-0.94%)
Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD

, /PRNewswire/ --Bionomics Limited (ASX: BNO, OTCQB: BNOEF, : AU000000BNO5) () today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (, a wholly owned subsidiary of...

BNOEF : 0.1049 (-0.94%)
BNO : 19.40 (+1.41%)
Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial

Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD Treatment

NM.CN : 1.010 (+1.00%)
BNO : 19.40 (+1.41%)
BNOEF : 0.1049 (-0.94%)
$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial

The new shares will be issued at per share representing a 263% premium to the Company's capital raise in and a 20% discount to the 30-day volume weighted average price (VWAP) as of . Completion of the...

BNOEF : 0.1049 (-0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.1149
2nd Resistance Point 0.1124
1st Resistance Point 0.1091
Last Price 0.1049
1st Support Level 0.1033
2nd Support Level 0.1008
3rd Support Level 0.0975

See More

52-Week High 0.3500
Fibonacci 61.8% 0.2346
Fibonacci 50% 0.1990
Fibonacci 38.2% 0.1634
Last Price 0.1049
52-Week Low 0.0480

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar